Zürcher Nachrichten - US approves first pill for treatment of alopecia

EUR -
AED 3.824403
AFN 72.783669
ALL 98.225528
AMD 409.464261
ANG 1.86853
AOA 955.849322
ARS 1064.387711
AUD 1.664145
AWG 1.874215
AZN 1.769528
BAM 1.951341
BBD 2.093416
BDT 123.896861
BGN 1.952286
BHD 0.392649
BIF 3065.294954
BMD 1.041231
BND 1.408082
BOB 7.164627
BRL 6.332664
BSD 1.036831
BTN 88.144565
BWP 14.330251
BYN 3.393046
BYR 20408.117808
BZD 2.084137
CAD 1.497322
CDF 2988.331476
CHF 0.932314
CLF 0.037326
CLP 1029.933253
CNY 7.600257
CNH 7.607949
COP 4571.001897
CRC 523.104561
CUC 1.041231
CUP 27.592608
CVE 110.014643
CZK 25.124215
DJF 184.628074
DKK 7.457658
DOP 63.135717
DZD 140.371386
EGP 53.084848
ERN 15.618458
ETB 129.24454
FJD 2.41152
FKP 0.824636
GBP 0.82807
GEL 2.926165
GGP 0.824636
GHS 15.24117
GIP 0.824636
GMD 74.968838
GNF 8957.529568
GTQ 7.988744
GYD 216.914291
HKD 8.091022
HNL 26.318854
HRK 7.468649
HTG 135.640025
HUF 414.44462
IDR 16858.094479
ILS 3.784951
IMP 0.824636
INR 88.601952
IQD 1358.196146
IRR 43822.821093
ISK 145.095638
JEP 0.824636
JMD 162.219284
JOD 0.738439
JPY 163.034814
KES 134.683497
KGS 90.587188
KHR 4166.478445
KMF 485.34358
KPW 937.106868
KRW 1512.007243
KWD 0.320761
KYD 0.864025
KZT 544.505654
LAK 22693.139901
LBP 92844.823907
LKR 304.404352
LRD 188.179957
LSL 19.088078
LTL 3.074483
LVL 0.62983
LYD 5.094358
MAD 10.434853
MDL 19.097357
MGA 4891.820837
MKD 61.496935
MMK 3381.876049
MNT 3538.101105
MOP 8.300232
MRU 41.233769
MUR 48.781555
MVR 16.046221
MWK 1797.378204
MXN 20.905883
MYR 4.674608
MZN 66.538512
NAD 19.088078
NGN 1610.210968
NIO 38.15281
NOK 11.77626
NPR 141.031704
NZD 1.841224
OMR 0.400872
PAB 1.036831
PEN 3.860777
PGK 4.204392
PHP 60.972335
PKR 288.591389
PLN 4.256512
PYG 8084.524626
QAR 3.779662
RON 4.975999
RSD 116.979118
RUB 105.531204
RWF 1445.297097
SAR 3.912738
SBD 8.729213
SCR 14.520152
SDG 626.296741
SEK 11.493389
SGD 1.411039
SHP 0.824636
SLE 23.794301
SLL 21834.086132
SOS 592.545869
SRD 36.579493
STD 21551.369123
SVC 9.072267
SYP 2616.123123
SZL 19.083389
THB 35.54656
TJS 11.342479
TMT 3.654719
TND 3.30375
TOP 2.438663
TRY 36.671935
TTD 7.036919
TWD 34.038856
TZS 2498.953516
UAH 43.482929
UGX 3803.308389
USD 1.041231
UYU 46.244319
UZS 13367.451677
VES 53.598498
VND 26496.713159
VUV 123.61697
WST 2.876699
XAF 654.461375
XAG 0.035009
XAU 0.000396
XCD 2.813977
XDR 0.790893
XOF 654.461375
XPF 119.331742
YER 260.698065
ZAR 19.131335
ZMK 9372.319369
ZMW 28.693428
ZWL 335.275796
  • CMSC

    0.0200

    23.86

    +0.08%

  • SCS

    -0.5800

    11.74

    -4.94%

  • BCC

    -0.2600

    122.75

    -0.21%

  • CMSD

    0.0000

    23.56

    0%

  • JRI

    0.1100

    12.06

    +0.91%

  • BCE

    0.0500

    23.16

    +0.22%

  • RIO

    -0.0900

    58.64

    -0.15%

  • GSK

    0.1700

    33.6

    +0.51%

  • NGG

    0.8200

    58.5

    +1.4%

  • RBGPF

    59.9600

    59.96

    +100%

  • BTI

    0.1131

    36.24

    +0.31%

  • AZN

    0.9100

    65.35

    +1.39%

  • BP

    0.1900

    28.6

    +0.66%

  • RYCEF

    -0.0100

    7.27

    -0.14%

  • RELX

    -0.3100

    45.47

    -0.68%

  • VOD

    0.0100

    8.39

    +0.12%

US approves first pill for treatment of alopecia
US approves first pill for treatment of alopecia / Photo: Mike Coppola - GETTY IMAGES NORTH AMERICA/AFP/File

US approves first pill for treatment of alopecia

The Food and Drug Administration on Monday approved a drug called baricitinib as the first oral tablet for treating severe alopecia areata, an autoimmune disorder affecting more than 300,000 people in the United States every year.

Text size:

Alopecia causes either temporary or permanent patchy hair loss that can affect any hair-bearing site of the body, leading to emotional distress. The condition has come to the fore recently through high-profile cases including Hollywood actress Jada Pinkett Smith and congresswoman Ayanna Pressley.

"Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia," said FDA official Kendall Marcus in a statement.

"Today's approval will help fulfill a significant unmet need for patients with severe alopecia areata."

Baricitinib, which is made by US pharmaceutical company Eli Lilly and known by the trade name Olumiant, belongs to a class of drugs called Janus kinase inhibitors. It works by interfering with the cellular pathway that leads to inflammation.

Its approval for use against alopecia was based on the results of two randomized, controlled clinical trials involving a total 1,200 adults with severe alopecia.

Each trial split participants into three groups: a placebo group, a group that received a two-milligram dose every day, and a group that received a four-milligram dose every day.

After 36 weeks, almost 40 percent of those on the higher dose grew back 80 percent of their scalp hair, compared to around 23 percent of the lower dose group, and five percent of the placebo group.

Around 45 percent of people in the higher dose group also saw significant eyebrow and eyelash regrowth.

The most common side effects included upper respiratory tract infections, headaches, acne, high cholesterol, and increase of an enzyme called creatinine phosphokinase.

Prior treatments for alopecia included topical or oral drugs, but these have been considered experimental and none was approved.

Baricitinib was previously approved for treatment of rheumatoid arthritis, and during the Covid pandemic its license was extended to the treatment of hospitalized Covid patients.

R.Schmid--NZN